data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
InflaRx
(NASDAQ:IFRX)
$2.99
-0.05[-1.64%]
At close: Aug 12
$2.99
After Hours: 5:05PM EDT
Day High/Low2.9 - 3.07
52 Week High/Low0.78 - 4.99
Open / Close3.04 / 2.99
Float / Outstanding39.8M / 44.2M
Vol / Avg.140.9K / 562.5K
Mkt Cap132.2M
P/E-
50d Avg. Price1.75
Div / Yield-
Payout Ratio-
EPS0.01
Total Float39.8M

InflaRx (NASDAQ:IFRX), Quotes and News Summary

InflaRx (NASDAQ: IFRX)

Day High/Low2.9 - 3.07
52 Week High/Low0.78 - 4.99
Open / Close3.04 / 2.99
Float / Outstanding39.8M / 44.2M
Vol / Avg.140.9K / 562.5K
Mkt Cap132.2M
P/E-
50d Avg. Price1.75
Div / Yield-
Payout Ratio-
EPS0.01
Total Float39.8M
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Read More

Earnings

see more
Q3 2022Est.ActualSurprise
EPS
(EXPECTED)2022-11-04
REV
Q2 2022Est.ActualSurprise
EPS-0.3100.010 0.3200
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

InflaRx Questions & Answers

Q
How do I buy InflaRx (IFRX) stock?
A

You can purchase shares of InflaRx (NASDAQ: IFRX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are InflaRx's (IFRX) competitors?
A

There are no as such competitors for InflaRx.

Q
What is the target price for InflaRx (IFRX) stock?
A

The latest price target for InflaRx (NASDAQ: IFRX) was reported by HC Wainwright & Co. on Monday, August 8, 2022. The analyst firm set a price target for 8.00 expecting IFRX to rise to within 12 months (a possible 167.56% upside). 8 analyst firms have reported ratings in the last year.

Q
Current Stock Price for InflaRx (IFRX)?
A

The stock price for InflaRx (NASDAQ: IFRX) is $2.99 last updated August 12, 2022, 8:00 PM UTC.

Q
Does InflaRx (IFRX) pay a dividend?
A

There are no upcoming dividends for InflaRx.

Q
When is InflaRx (NASDAQ:IFRX) reporting earnings?
A

InflaRx’s Q3 earnings are confirmed for Friday, November 4, 2022.

Q
Is InflaRx (IFRX) going to split?
A

There is no upcoming split for InflaRx.

Q
What sector and industry does InflaRx (IFRX) operate in?
A

InflaRx is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.